300233 金城医药
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)1.5651.1895.2614.7727.808
总资产报酬率 ROA (%)1.1110.8193.4162.9764.925
投入资产回报率 ROIC (%)1.3170.9874.2343.7736.180

边际利润分析
销售毛利率 (%)34.61236.03740.13143.72746.223
营业利润率 (%)10.2613.0777.9196.38310.091
息税前利润/营业总收入 (%)10.7133.0537.9316.66110.288
净利润/营业总收入 (%)7.8641.5456.1585.4638.155

收益指标分析
经营活动净收益/利润总额(%)98.126137.488100.661108.534107.602
价值变动净收益/利润总额(%)0.9333.463-0.5880.2260.856
营业外收支净额/利润总额(%)-1.108-7.9410.488-0.196-2.258

偿债能力分析
流动比率 (X)1.7331.7071.8351.4801.357
速动比率 (X)1.3771.3271.3481.1671.016
资产负债率 (%)27.37828.26031.63036.08837.192
带息债务/全部投入资本 (%)12.46512.09014.08216.79116.826
股东权益/带息债务 (%)674.310696.812580.843471.687469.060
股东权益/负债合计 (%)260.928249.732212.483173.962166.483
利息保障倍数 (X)18.98815.115-297.68422.93024.528

营运能力分析
应收账款周转天数 (天)64.70272.70062.88560.46460.513
存货周转天数 (天)83.560109.34698.05297.67892.665